Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells 75,000 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $79.99, for a total transaction of $5,999,250.00. Following the completion of the transaction, the director directly owned 701,477 shares in the company, valued at $56,111,145.23. This trade represents a 9.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Liquidia Trading Down 0.3%

Shares of NASDAQ:LQDA traded down $0.26 during trading on Tuesday, hitting $84.16. 276,611 shares of the company’s stock were exchanged, compared to its average volume of 1,803,461. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The firm has a market cap of $7.48 billion, a P/E ratio of 604.11 and a beta of 0.55. The firm has a 50-day moving average price of $71.77 and a two-hundred day moving average price of $50.58. Liquidia Corporation has a 1-year low of $16.82 and a 1-year high of $91.10.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. The firm’s revenue was up 4187.1% on a year-over-year basis. Equities analysts predict that Liquidia Corporation will post 3.02 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Liquidia in the 4th quarter valued at $25,000. Covestor Ltd lifted its holdings in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares in the last quarter. NewEdge Advisors LLC bought a new position in Liquidia during the second quarter worth about $25,000. Fluent Financial LLC acquired a new position in Liquidia in the second quarter valued at about $287,000. Finally, Fulcrum Equity Management bought a new stake in shares of Liquidia in the second quarter worth about $399,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Ratings Changes

LQDA has been the subject of a number of analyst reports. Piper Sandler set a $129.00 price objective on Liquidia in a research note on Friday. Wall Street Zen lowered Liquidia from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. HC Wainwright set a $36.00 target price on Liquidia in a research report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $86.18.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).